Outlook Therapeutics, Inc. cotiza a 0.58 USD y tiene una capitalización bursátil de $142M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clin…
| Periodo | 2026-12 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | — | $-0.17 | $-0.22 |
| Estimado | $-0.07 | $-0.07 | $-0.12 | $-0.17 |
| Sorpresa | — | — | -41.7% | -29.4% |
| Métrica | OTLK | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 4.0% | 57.0% | -53.0% |
| Operating Margin | -4744.3% | -38.6% | -4705.6% |
| Net Margin | -4416.2% | -33.6% | -4382.7% |
| FCF Margin | — | -13.9% | — |
| ROE | — | -40.4% | — |
| ROA | -335.9% | -32.0% | -303.9% |
| Current Ratio | 0.38 | 2.84 | -2.46 |
| Debt / Equity | — | 0.28 | — |